<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151189</url>
  </required_header>
  <id_info>
    <org_study_id>C-030-485</org_study_id>
    <nct_id>NCT01151189</nct_id>
  </id_info>
  <brief_title>Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)</brief_title>
  <official_title>A Phase II, Proof of Concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Protective Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in Healthy, HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aeras</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, proof of concept, randomized, double-blind, placebo-controlled study to
      evaluate the protective efficacy against TB disease, safety, and immunogenicity of
      MVA85A/AERAS-485 in healthy, HIV-infected adults.

      This study consists of 650 adults subjects (ages 18-50 years of age inclusive) who will
      receive study vaccine or placebo at Study Day 0 and again 6-9 months later. Samples for
      real-time evaluation of immunogenicity were to be collected from 70 subjects (immunogenicity
      analysis set).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II multi-country trial was conducted as a randomized, double-blind,
      placebo-controlled trial in 650 HIV-positive adults with no evidence of active TB disease.
      Subjects were stratified at the time of randomization by whether or not they were receiving
      anti-retroviral therapy (ART) and then randomized in a ratio of 1:1 to receive either
      MVA85A/AERAS-485 at 1 x 10^8 plaque forming units (pfu) or placebo (Candin). Randomization of
      each group was capped so that at least 50% of the subjects randomized were receiving ART at
      randomization. Subjects were to receive an intradermal injection of MVA85A/AERAS-485 or
      placebo on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485
      or placebo. The minimum follow-up period for each subject was 6 months after their last
      vaccination, during which subjects were followed for safety, clinical signs and symptoms of
      TB, and immunogenicity. All subjects were to continue to be followed every 3 months until the
      last subject enrolled had been followed for 6 months after their last vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Adverse Events (AEs) are recorded for 28 days post vaccination, Serious Adverse Events (SAEs) for at least 6 months post second vaccination.</time_frame>
    <description>The primary objective of this study is to evaluate the safety of MVA85A/AERAS-485 compared to placebo in HIV-infected, African adult subjects without active TB disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of TB Cases</measure>
    <time_frame>For at least 6 months post second vaccination up to 33 months total follow-up.</time_frame>
    <description>Efficacy of MVA85A/AERAS-485 in the prevention of TB disease compared to control subjects who received placebo in HIV-infected, African adult subjects without active TB disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ Lymphocyte Counts Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in Anti-retroviral Therapy Negative (ART -)Subjects</measure>
    <time_frame>Up to 6 months post second vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ Lymphocyte Counts Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART+ Subjects</measure>
    <time_frame>Up to 6 months post second vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 Viral Load Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART - Participants</measure>
    <time_frame>Up to 6 months post second vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 Viral Load Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART+ Participants.</measure>
    <time_frame>Up tp 6 months post second vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Counts of Spot-forming Units After Stimulation With AG85A Peptide Pool.</measure>
    <time_frame>28 days post second vaccination.</time_frame>
    <description>Immunogenicity of MVA85A/AERAS-485 compared to placebo as described by the ex vivo interferon (IFN)-γ enzyme linked immunospot (ELISpot).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MVA85A/AERAS-485 Compared to Placebo as Described by Flow Cytometric Intracellular Cytokine Staining (ICS) of CD4+ and CD8+ T Cells After Stimulation With a Peptide Pool of Mycobacterial Antigens.</measure>
    <time_frame>7 days post second vaccination.</time_frame>
    <description>The antigen-specific negative control-subtracted response for any cytokine (Interferon gamma [INFγ] , Interleukin 2 [IL2], Interleukin 17 [IL17] and tumor necrosis factor [TNF]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QuantiFERON (QFN) Conversion Rate in MVA85A/AERAS-485 Recipients Compared to Control Subjects Without a Diagnosis of Tuberculosis During the Trial.</measure>
    <time_frame>For at least 6 months post second vaccination up to 33 months total follow-up.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>Tuberculosis</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo is a licensed product manufactured by Allermed, Inc. and is used for evaluation of delayed-type of hypersensitivity reactions in adults.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVA85A/AERAS-485</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10^8 pfu.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA85A/AERAS-485</intervention_name>
    <description>Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.</description>
    <arm_group_label>MVA85A/AERAS-485</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Candida albicans Skin Test Antigen</other_name>
    <other_name>Candin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has completed the written informed consent process prior to undergoing any screening
             evaluations.

          -  Either males or females aged 18-50 years (inclusive) on Study Day 0

          -  In general good health, confirmed by medical history and physical examination

          -  Has ability to complete follow-up period as required by the protocol

          -  Has laboratory evidence of human immunodeficiency virus (HIV) infection, defined as a
             positive HIV-1 ELISA test plus a positive confirmatory test (e.g., a second HIV-1
             ELISA, polymerase chain reaction (PCR), or rapid ELISA) diagnosed prior to
             randomization

          -  Is willing to allow the investigators to discuss the subject's medical history with
             the subject's HIV physician

          -  Has 2 CD4+ lymphocyte count test results &gt;350 cells/mm3, performed at least 4 weeks
             apart, one performed within 6 months prior to randomization and one within 30 days
             prior to randomization

          -  Has either: a) a negative QuantiFERON-TB Gold In-Tube test result and tuberculin
             purified protein derivative (PPD) skin test ≤5 mm induration within 30 days prior to
             randomization or; b) a positive QuantiFERON-TB Gold In-Tube test result and/or
             tuberculin PPD skin test &gt;5 mm and has completed 6 months of isoniazid preventive
             therapy prior to randomization or; c) a positive QuantiFERON-TB Gold In-Tube test
             result and/or tuberculin PPD skin test &gt;5 mm and has completed treatment for TB
             disease within 3 year prior to randomization

          -  Females: Ability to avoid pregnancy during the trial. Women physically capable of
             pregnancy (not sterilized and still menstruating or within 1 year of the last menses
             if menopausal) in sexual relationships with men must avoid pregnancy by using an
             acceptable method of avoiding pregnancy from 28 days prior to administration of the
             study vaccine through the end of the study. Acceptable methods of avoiding pregnancy
             include a sterile sexual partner, sexual abstinence (not engaging in sexual
             intercourse), hormonal contraceptives (oral, injection, transdermal patch, or
             implant), vaginal ring, intrauterine device (IUD), or the use of a condom or a
             diaphragm combined with spermicide.

          -  Has completed the written informed consent process for simultaneous enrollment in
             Aeras Vaccine Development Registry protocol

        Exclusion Criteria:

          -  Acute illness

          -  Fever (temperature &gt; 37.5°C)

          -  Significant symptomatic infection

          -  Any evidence of active tuberculosis (TB) disease, as determined by any clinical,
             radiological, or microbiology measurements.

          -  Any AIDS defining illness by WHO criteria

          -  Has received antiretroviral therapy (ART) in the two months prior to study entry
             (women who have received ART as part of the Prevention of Mother-to-Child Transmission
             [PMTCT] program and completed this more than 2 months prior to randomization ARE
             eligible)

          -  Use of any investigational or non-registered drug, vaccine or medical device other
             than the study vaccine within 182 days preceding dosing of study vaccine, or planned
             use during the study period

          -  Previous receipt of a recombinant modified vaccinia Ankara (MVA) or fusion protein
             (FP) vector at any time.

          -  Is enrolled in any other clinical product trial

          -  Administration of methotrexate, azathioprine, cyclophosphamide, oral corticosteroids
             (for corticosteroids, this will mean prednisolone, or equivalent, ≥0.5 mg/kg/day;
             inhaled and topical steroids are allowed) and other immunosuppressive therapies, or
             blood products or blood derivatives within the six months prior to randomization

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine, e.g. egg products

          -  Presence of any history of cancer [except basal cell carcinoma of the skin and
             cervical carcinoma in situ], or renal failure

          -  Evidence of severe depression, schizophrenia or mania

          -  Pregnant females and females who are breast-feeding

          -  Any history of anaphylaxis in reaction to vaccination

          -  Principal investigator assessment of lack of willingness to participate and comply
             with the protocol, or increase in the participant's risk of adverse outcome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Souleymane Mboup</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Aristide Le Dantec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Wilkinson</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Landry</last_name>
    <role>Study Director</role>
    <affiliation>Aeras</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Aristide Le Dantec</name>
      <address>
        <city>Dakar</city>
        <zip>7325</zip>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Senegal</country>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, Dieye TN, Esmail H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, Wilkinson RJ, McShane H; MVA85A 030 trial investigators. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015 Mar;3(3):190-200. doi: 10.1016/S2213-2600(15)00037-5. Epub 2015 Feb 26.</citation>
    <PMID>25726088</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <results_first_submitted>June 30, 2015</results_first_submitted>
  <results_first_submitted_qc>July 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2015</results_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>The placebo is a licensed product manufactured by Allermed, Inc. and is used for evaluation of delayed-type of hypersensitivity reactions in adults.
Placebo: Subjects were to receive an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.</description>
        </group>
        <group group_id="P2">
          <title>MVA85A/AERAS-485</title>
          <description>MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10^8 pfu.
MVA85A/AERAS-485: Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="326"/>
                <participants group_id="P2" count="324"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
                <participants group_id="P2" count="324"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety:
All randomized subjects who received a dose of study vaccine, based on actual treatment received.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: Subjects were to receive an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.</description>
        </group>
        <group group_id="B2">
          <title>MVA85A/AERAS-485</title>
          <description>MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10^8 pfu.
MVA85A/AERAS-485: Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="325"/>
            <count group_id="B2" value="324"/>
            <count group_id="B3" value="649"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.8" spread="6.61"/>
                    <measurement group_id="B2" value="37.7" spread="6.69"/>
                    <measurement group_id="B3" value="37.7" spread="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="255"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coloured</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Senegal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <description>The primary objective of this study is to evaluate the safety of MVA85A/AERAS-485 compared to placebo in HIV-infected, African adult subjects without active TB disease.</description>
        <time_frame>Adverse Events (AEs) are recorded for 28 days post vaccination, Serious Adverse Events (SAEs) for at least 6 months post second vaccination.</time_frame>
        <population>Safety:
All randomized subjects who received a dose of study vaccine, based on actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>MVA85A/AERAS-485</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <description>The primary objective of this study is to evaluate the safety of MVA85A/AERAS-485 compared to placebo in HIV-infected, African adult subjects without active TB disease.</description>
          <population>Safety:
All randomized subjects who received a dose of study vaccine, based on actual treatment received.</population>
          <units>percentage of participants with an AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of TB Cases</title>
        <description>Efficacy of MVA85A/AERAS-485 in the prevention of TB disease compared to control subjects who received placebo in HIV-infected, African adult subjects without active TB disease.</description>
        <time_frame>For at least 6 months post second vaccination up to 33 months total follow-up.</time_frame>
        <population>Per protocol:
All randomized subjects who received a dose of study vaccine and had no major protocol deviations, were still ongoing in the study 28 days after Study Day 0, and did not have TB diagnosed within 28 days after Study Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>MVA85A/AERAS-485</title>
          </group>
        </group_list>
        <measure>
          <title>Number of TB Cases</title>
          <description>Efficacy of MVA85A/AERAS-485 in the prevention of TB disease compared to control subjects who received placebo in HIV-infected, African adult subjects without active TB disease.</description>
          <population>Per protocol:
All randomized subjects who received a dose of study vaccine and had no major protocol deviations, were still ongoing in the study 28 days after Study Day 0, and did not have TB diagnosed within 28 days after Study Day 0.</population>
          <units>participants with TB</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ Lymphocyte Counts Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in Anti-retroviral Therapy Negative (ART -)Subjects</title>
        <time_frame>Up to 6 months post second vaccination.</time_frame>
        <population>Safety:
All randomized ART negative subjects who received a dose of study vaccine, based on actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>MVA85A/AERAS-485</title>
          </group>
        </group_list>
        <measure>
          <title>CD4+ Lymphocyte Counts Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in Anti-retroviral Therapy Negative (ART -)Subjects</title>
          <population>Safety:
All randomized ART negative subjects who received a dose of study vaccine, based on actual treatment received.</population>
          <units>cells/mm^3</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="540.60" spread="1.333"/>
                    <measurement group_id="O2" value="541.10" spread="1.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="557.39" spread="1.395"/>
                    <measurement group_id="O2" value="484.64" spread="1.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ Lymphocyte Counts Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART+ Subjects</title>
        <time_frame>Up to 6 months post second vaccination.</time_frame>
        <population>Safety:
All randomized ART positive subjects who received a dose of study vaccine, based on actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>MVA85A/AERAS-485</title>
          </group>
        </group_list>
        <measure>
          <title>CD4+ Lymphocyte Counts Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART+ Subjects</title>
          <population>Safety:
All randomized ART positive subjects who received a dose of study vaccine, based on actual treatment received.</population>
          <units>cells/mm^3</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="568.07" spread="1.387"/>
                    <measurement group_id="O2" value="564.27" spread="1.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="606.07" spread="1.430"/>
                    <measurement group_id="O2" value="604.24" spread="1.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 Viral Load Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART - Participants</title>
        <time_frame>Up to 6 months post second vaccination.</time_frame>
        <population>Safety:
All randomized ART - subjects who received a dose of study vaccine, based on actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>MVA85A/AERAS-485</title>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 Viral Load Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART - Participants</title>
          <population>Safety:
All randomized ART - subjects who received a dose of study vaccine, based on actual treatment received.</population>
          <units>copies/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6918.76" spread="8.673"/>
                    <measurement group_id="O2" value="9616.55" spread="9.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9090.32" spread="14.101"/>
                    <measurement group_id="O2" value="6437.59" spread="25.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 Viral Load Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART+ Participants.</title>
        <time_frame>Up tp 6 months post second vaccination</time_frame>
        <population>Safety:
All randomized ART + subjects who received a dose of study vaccine, based on actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>MVA85A/AERAS-485</title>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 Viral Load Before and After Administration of MVA85A/AERAS-485 Compared to Placebo in ART+ Participants.</title>
          <population>Safety:
All randomized ART + subjects who received a dose of study vaccine, based on actual treatment received.</population>
          <units>copies/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.32" spread="1.339"/>
                    <measurement group_id="O2" value="26.87" spread="1.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.30" spread="1.580"/>
                    <measurement group_id="O2" value="29.39" spread="2.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Counts of Spot-forming Units After Stimulation With AG85A Peptide Pool.</title>
        <description>Immunogenicity of MVA85A/AERAS-485 compared to placebo as described by the ex vivo interferon (IFN)-γ enzyme linked immunospot (ELISpot).</description>
        <time_frame>28 days post second vaccination.</time_frame>
        <population>First 70 patients enrolled who also had pre-vaccination results available were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>MVA85A/AERAS-485</title>
          </group>
        </group_list>
        <measure>
          <title>Counts of Spot-forming Units After Stimulation With AG85A Peptide Pool.</title>
          <description>Immunogenicity of MVA85A/AERAS-485 compared to placebo as described by the ex vivo interferon (IFN)-γ enzyme linked immunospot (ELISpot).</description>
          <population>First 70 patients enrolled who also had pre-vaccination results available were analyzed.</population>
          <units>SFU - background/10^6 PBMC</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" lower_limit="4.00" upper_limit="30.00"/>
                    <measurement group_id="O2" value="254.00" lower_limit="92.00" upper_limit="462.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of MVA85A/AERAS-485 Compared to Placebo as Described by Flow Cytometric Intracellular Cytokine Staining (ICS) of CD4+ and CD8+ T Cells After Stimulation With a Peptide Pool of Mycobacterial Antigens.</title>
        <description>The antigen-specific negative control-subtracted response for any cytokine (Interferon gamma [INFγ] , Interleukin 2 [IL2], Interleukin 17 [IL17] and tumor necrosis factor [TNF]).</description>
        <time_frame>7 days post second vaccination.</time_frame>
        <population>First 70 patients enrolled who also had pre-vaccination results available were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>MVA85A/AERAS-485</title>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of MVA85A/AERAS-485 Compared to Placebo as Described by Flow Cytometric Intracellular Cytokine Staining (ICS) of CD4+ and CD8+ T Cells After Stimulation With a Peptide Pool of Mycobacterial Antigens.</title>
          <description>The antigen-specific negative control-subtracted response for any cytokine (Interferon gamma [INFγ] , Interleukin 2 [IL2], Interleukin 17 [IL17] and tumor necrosis factor [TNF]).</description>
          <population>First 70 patients enrolled who also had pre-vaccination results available were analyzed.</population>
          <units>Percent responding TCells</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.10" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.20" lower_limit="0.16" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.01" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QuantiFERON (QFN) Conversion Rate in MVA85A/AERAS-485 Recipients Compared to Control Subjects Without a Diagnosis of Tuberculosis During the Trial.</title>
        <time_frame>For at least 6 months post second vaccination up to 33 months total follow-up.</time_frame>
        <population>Per protocol:
All randomized subjects who received a dose of study vaccine and had no major protocol deviations, were still ongoing in the study 28 days after Study Day 0, and did not have TB diagnosed within 28 days after Study Day 0 (QFT negative at baseline subgroup).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>MVA85A/AERAS-485</title>
          </group>
        </group_list>
        <measure>
          <title>QuantiFERON (QFN) Conversion Rate in MVA85A/AERAS-485 Recipients Compared to Control Subjects Without a Diagnosis of Tuberculosis During the Trial.</title>
          <population>Per protocol:
All randomized subjects who received a dose of study vaccine and had no major protocol deviations, were still ongoing in the study 28 days after Study Day 0, and did not have TB diagnosed within 28 days after Study Day 0 (QFT negative at baseline subgroup).</population>
          <units>participants who converted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs reported 28 after each vaccine. SAEs reported for the duration of the study; for at least 6 months after last vaccine up to 33 months total follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>MVA85A/AERAS-485</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital anomaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Death neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Eye infection syphilitic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Meningorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="310" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="320" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="51" subjects_affected="45" subjects_at_risk="325"/>
                <counts group_id="E2" events="41" subjects_affected="40" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="48" subjects_at_risk="325"/>
                <counts group_id="E2" events="49" subjects_affected="44" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="139" subjects_affected="122" subjects_at_risk="325"/>
                <counts group_id="E2" events="157" subjects_affected="128" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="325"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="45" subjects_affected="37" subjects_at_risk="325"/>
                <counts group_id="E2" events="43" subjects_affected="37" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="94" subjects_affected="70" subjects_at_risk="325"/>
                <counts group_id="E2" events="146" subjects_affected="118" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Injection site discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="325"/>
                <counts group_id="E2" events="46" subjects_affected="42" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Injection site exfoliation</sub_title>
                <counts group_id="E1" events="145" subjects_affected="111" subjects_at_risk="325"/>
                <counts group_id="E2" events="364" subjects_affected="243" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="128" subjects_affected="95" subjects_at_risk="325"/>
                <counts group_id="E2" events="370" subjects_affected="229" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="247" subjects_affected="161" subjects_at_risk="325"/>
                <counts group_id="E2" events="420" subjects_affected="243" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="325"/>
                <counts group_id="E2" events="74" subjects_affected="59" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Injection site ulcer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="325"/>
                <counts group_id="E2" events="130" subjects_affected="106" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Injection site vesicles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="145" subjects_affected="108" subjects_at_risk="325"/>
                <counts group_id="E2" events="271" subjects_affected="180" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="77" subjects_affected="59" subjects_at_risk="325"/>
                <counts group_id="E2" events="143" subjects_affected="115" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="41" subjects_affected="39" subjects_at_risk="325"/>
                <counts group_id="E2" events="39" subjects_affected="36" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="325"/>
                <counts group_id="E2" events="33" subjects_affected="32" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="40" subjects_affected="39" subjects_at_risk="325"/>
                <counts group_id="E2" events="38" subjects_affected="33" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="48" subjects_affected="46" subjects_at_risk="325"/>
                <counts group_id="E2" events="53" subjects_affected="48" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="325"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="325"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="70" subjects_affected="53" subjects_at_risk="325"/>
                <counts group_id="E2" events="111" subjects_affected="85" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="89" subjects_affected="68" subjects_at_risk="325"/>
                <counts group_id="E2" events="174" subjects_affected="127" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="136" subjects_affected="91" subjects_at_risk="325"/>
                <counts group_id="E2" events="177" subjects_affected="121" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="58" subjects_affected="52" subjects_at_risk="325"/>
                <counts group_id="E2" events="57" subjects_affected="49" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diastolic hypertension</sub_title>
                <counts group_id="E1" events="61" subjects_affected="51" subjects_at_risk="325"/>
                <counts group_id="E2" events="65" subjects_affected="56" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" events="40" subjects_affected="30" subjects_at_risk="325"/>
                <counts group_id="E2" events="51" subjects_affected="45" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Product Director; Bernard Landry</name_or_title>
      <organization>Aeras</organization>
      <phone>301-547-2919</phone>
      <email>blandry@aeras.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

